Low-dose eye drops can manage adult myopia for 24 hours
May 4, 2026
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia.
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia.
A new study published in The Journal of Prevention of Alzheimer’s Disease suggests that these oral capsules may actually be linked to a faster decline in cognitive function.
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.
TaeWoong Medical, the fully covered, self-expanding metallic device, is intended to aid EUS drainage procedures.
https://medtechspectrum.com/news/40/25517/unm-scientist-studies-where-brain-cancer-cells-hide-and-how-to-fight-them.html
Scientists have developed a way to turn the body’s own immune cells into cancer-fighting agents—without removing them from the body—by using red blood cells to deliver genetic instructions.
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers.
Founded by Jake Donoghue PhD ’19 and former MIT researcher Jarrett Revels, the company is creating an AI-driven platform to help diagnose and treat disease.
Philips (NYSE:PHG) announced that it received FDA 510(k) clearance for its Smart Fit TorsoCardiac magnetic resonance (MR) 1.5T coil.